Ligand Pharmaceuticals | LGND - Selling And Administration Expenses


Ligand Pharmaceuticals reported $28.45M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Amgen USD 1.94B 237M Dec/2025
Arrowhead Research USD 37.18M 6.23M Sep/2025
Baxter International USD 708M 10M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
Gilead Sciences USD 1.35B 6M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
Insmed USD 186.38M 109.94M Sep/2025
Ionis Pharmaceuticals USD 86.56M 4.04M Sep/2025
Ligand Pharmaceuticals USD 28.45M 8.27M Sep/2025
MacroGenics USD 9.9M 600K Sep/2025
Merck USD 2.85B 215M Dec/2025
Pacira USD 91.8M 14.6M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Veracyte USD 51.73M 5.91M Sep/2025